Technical Analysis for RCEL - Avita Medical Limited

Grade Last Price % Change Price Change
D 15.83 -3.65% -0.60
RCEL closed down 3.65 percent on Monday, March 18, 2024, on 1.2 times normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
3 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down

Date Alert Name Type % Chg
Fell Below 50 DMA Bearish 0.00%
MACD Bearish Centerline Cross Bearish 0.00%
Expansion Pivot Sell Setup Bearish Swing Setup 0.00%
Stochastic Reached Oversold Weakness 0.00%
Outside Day Range Expansion 0.00%
Below Lower BB Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
50 DMA Support Bullish -3.65%

   Recent Intraday Alerts

Alert Time
Down 5% about 12 hours ago
60 Minute Opening Range Breakdown about 15 hours ago
Down 3% about 15 hours ago
Fell Below Lower Bollinger Band about 15 hours ago
Down 2 % about 15 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Avita Medical Limited Description

Avita Medical Limited operates as a regenerative medicine company in the Asia Pacific, Europe, the Middle East, Africa, and the Americas. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin. Its lead product is RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of the patient's own skin for use in the treatment of acute thermal burns in patients 18 years and older. The company has a preclinical research collaboration with the University of Colorado School of Medicine to establish and explore development of a spray-on treatment for patients with epidermolysis bullosa. The company is based in Valencia, California.


Classification

Sector: Healthcare
Industry: Medical Devices
Keywords: Medicine Clinical Medicine Rare Diseases Clinical Research Dermatology Wound Regenerative Medicine Suspension Platform Technology Burns Genodermatoses Aesthetics Epidermolysis Bullosa Skin Chronic Wound Chronic Wounds Treatment Solutions

Is RCEL a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 21.704
52 Week Low 9.1624
Average Volume 174,466
200-Day Moving Average 14.90
50-Day Moving Average 16.40
20-Day Moving Average 17.17
10-Day Moving Average 16.72
Average True Range 0.88
RSI (14) 41.52
ADX 21.11
+DI 15.53
-DI 30.61
Chandelier Exit (Long, 3 ATRs) 16.29
Chandelier Exit (Short, 3 ATRs) 18.01
Upper Bollinger Bands 18.48
Lower Bollinger Band 15.87
Percent B (%b) -0.02
BandWidth 15.18
MACD Line -0.06
MACD Signal Line 0.17
MACD Histogram -0.2231
Fundamentals Value
Market Cap 404.47 Million
Num Shares 25.6 Million
EPS -1.34
Price-to-Earnings (P/E) Ratio -11.81
Price-to-Sales 10.13
Price-to-Book 7.30
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 17.62
Resistance 3 (R3) 17.74 17.26 17.32
Resistance 2 (R2) 17.26 16.81 17.20 17.22
Resistance 1 (R1) 16.55 16.53 16.31 16.43 17.12
Pivot Point 16.07 16.07 15.96 16.01 16.07
Support 1 (S1) 15.36 15.62 15.12 15.24 14.54
Support 2 (S2) 14.88 15.34 14.82 14.44
Support 3 (S3) 14.17 14.88 14.34
Support 4 (S4) 14.05